Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + famitinib vs docetaxel or famitinib in previously treated NSCLC
CTR20212724Phase 3Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, famitinib, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Nov 2021; status: terminated.
02
Drugs
camrelizumabfamitinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212724.